leadf
logo-loader
viewClerkenwell Health

Clerkenwell Health partners with Danish synthetic biology drug developer Octarine Bio

Clerkenwell Health CEO Tom McDonald tells Proactive the privately-held UK-based psychedelic-specialist contract research organization has partnered with Danish synthetic biology drug developer Octarine Bio to help advance patient access to psychedelics.

McDonald says the synthetic biology drug development company produces psilocybin from sugar using fermentation. The two will partners to expedite its clinical development with biosynthetic psilocybin and expects to be able to fast-track steps leading to human clinical trials.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Altiplano Metals receives exploitation permit at Maria Luisa which allows...

Altiplano Metals CEO Alastair McIntyre joined Steve Darling from Proactive to share news the company has announced the Chilean mining authority has approved their exploitation license on the Maria Luisa project is located in Chile. McIntyre telling Proactive this now allows the company to...

3 hours, 24 minutes ago

2 min read